Initial Diagnosis of HR+/HER2- Breast Cancer

Commentary
Video

Valerie Frank and Sara M. Tolaney, MD, MPH, share advice for patients on managing treatment with antibody-drug conjugates and the importance of participating in clinical trials for HR+/HER2- metastatic breast cancer.

Transcript

I'm Valerie. I live in eastern Massachusetts. I was diagnosed at age 44. It was not from a mammogram — I had skipped my mammogram that year, and don't recommend that at all. I just found a lump while I was sitting and reading a book, and I had never had a lump before in my life.

I called my OBGYN and they didn't call back. So I panicked and just went in. And the nurse practitioner who was there said, "I don't like the way this feels" and sent me directly to to have a biopsy. And while they were biopsy, seeing while they were doing the biopsy, the nurse who is part of the tech team said, "Oh, honey, it's definitely breast cancer, but it's just gonna be a bump in the road."

And I went home just totally in shock and and we ended up seeing one oncologist at who was affiliated with my OBGYN office. Shortly thereafter, they told me it was stage 2, and that they did think there was lymph node involvement, but that that they thought it was still caught early, and that a very good chance of everything being fine. And and then we met with a doctor at Dana-Farber, and very quickly realized that ... I wanted to be treated at Dana-Farber.

They also thought it was stage 2, although by the time I was finished with with chemo and had it and had a lumpectomy, it was clear that it was really stage 3 all along.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Related Content